The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Results of DREAMM-4: safety and efficacy of belantamab mafodotin with pembrolizumab in R/R myeloma
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, shares insight into the safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory (R/R) multiple myeloma (MM), investigated in the Phase I/II DREAMM-4 clinical trial (NCT03848845). The addition of pembrolizumab did not improve the overall response rate (ORR), meaning this combination will not proceed to further testing. However, Dr Suvannasankha highlights that, as the field of immunotherapy in myeloma evolves, a combination strategy of belantamab mafodotin and a checkpoint inhibitor may still be of value in some subgroups of patients. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
